Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Glenmark Pharmaceuticals Dividend Announcement
• Glenmark Pharmaceuticals announced a annually dividend of ₹2.50 per ordinary share which will be made payable on 2024-10-27. Ex dividend date: 2024-09-13
• Glenmark Pharmaceuticals annual dividend for 2024 was ₹2.50
• Glenmark Pharmaceuticals annual dividend for 2023 was ₹2.50
• Glenmark Pharmaceuticals's trailing twelve-month (TTM) dividend yield is 0.16%
• Glenmark Pharmaceuticals's dividend growth over the last five years (2018-2023) was 4.56% year
• Glenmark Pharmaceuticals's dividend growth over the last ten years (2013-2023) was 2.26% year
Glenmark Pharmaceuticals Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-09-13 | ₹2.50 | annually | 2024-10-27 |
2023-09-18 | ₹2.50 | annually | 2023-10-29 |
2022-09-12 | ₹2.50 | annually | 2022-10-27 |
2021-09-08 | ₹2.50 | annually | 2021-10-24 |
2020-09-17 | ₹2.50 | annually | 2020-10-29 |
2019-09-19 | ₹2.00 | annually | 2019-10-27 |
2018-09-19 | ₹2.00 | annually | 2018-10-28 |
2017-09-20 | ₹2.00 | annually | 2017-10-29 |
2016-08-03 | ₹2.00 | annually | 2016-08-31 |
2015-09-10 | ₹2.00 | annually | 2015-10-12 |
2014-07-10 | ₹2.00 | annually | 2014-08-24 |
2013-07-18 | ₹2.00 | annually | 2013-09-01 |
Glenmark Pharmaceuticals Dividend per year
Glenmark Pharmaceuticals Dividend growth
Glenmark Pharmaceuticals Dividend Yield
Glenmark Pharmaceuticals current trailing twelve-month (TTM) dividend yield is 0.16%. Interested in purchasing Glenmark Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:
Glenmark Pharmaceuticals Financial Ratios
Glenmark Pharmaceuticals Dividend FAQ
Other factors to consider when evaluating Glenmark Pharmaceuticals as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Glenmark Pharmaceuticals stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Glenmark Pharmaceuticals's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Glenmark Pharmaceuticals publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Glenmark Pharmaceuticals distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Glenmark Pharmaceuticals are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Glenmark Pharmaceuticals sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Glenmark Pharmaceuticals distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Glenmark Pharmaceuticals declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Glenmark Pharmaceuticals's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Glenmark Pharmaceuticals's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.